Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/109152DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES
WO 27.05.2022
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No PCT/US2021/059915 Applicant GREFFEX, INC. Inventor STAERZ, Uwe, D.
The present disclosure provides a universal influenza virus vaccine. A composition for a universal influenza virus vaccine comprises at least two, preferably more than two, different influenza hemagglutinin (HA) derived antigens. The HA proteins from which the antigens are derived have a hypervariable region located between conserved cysteines at positions 52 and 277, and the hypervariable region is deleted in the antigens. The at least two antigens each have a similarity with HA molecules of more than one influenza serotype in excess of 60, or 70, or 80, as calculated by the emboss explorer cons program.
2.WO/2022/105880FUSION GENE, RECOMBINANT NOVEL CORONAVIRUS HIGH-EFFICIENCY IMMUNE DNA VACCINE, CONSTRUCTION METHOD THEREFOR AND USE THEREOF
WO 27.05.2022
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/CN2021/131786 Applicant AURORA GENEVAC BIOTECH CO., LTD. Inventor YU, Jiyun
A fusion gene, a recombinant novel coronavirus high-efficiency immune DNA vaccine, a construction method therefor and use thereof. The immune DNA vaccine ZD-nCor19 provided therein uses RBD protein, segment 301-538aa of the S2 subunit and segment 138-369aa of the N protein of the novel coronavirus as target antigens, and has a specific immune synergism molecule introduced at a suitable position, and thus can simultaneously efficiently induce humoral immunity and cellular immunity, and can avoid safety problems associated with ADE that may be generated by the full-length S protein and the full-length N protein, thereby achieving dual effects of prevention and treatment.
3.WO/2022/108460PEPTIDE-BASED ANTIGENIC CONSTRUCTS RECOGNIZED BY IMMUNOGLOBULINS THAT BIND TO PROTEIN EPITOPES OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO 27.05.2022
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
Appl.No PCT/PH2021/050039 Applicant UNIVERSITY OF THE PHILIPPINES MANILA Inventor CAOILI, Salvador Eugenio
The invention provides: peptide-based antigenic constructs, each comprising a plurality of monomeric units and recognized by immunoglobulins that bind to protein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); methods for producing said constructs using peptidic precursors that comprise artificial sequences, said monomeric units being derived from said precursors; methods and testing systems for detecting said immunoglobulins; and use of said constructs in processes for detecting and producing said immunoglobulins.
4.WO/2022/109164DEVELOPMENT OF A NOVEL ELISA-BASED POINT-OF-CARE ANTIGEN TEST FOR SARS-COV-2
WO 27.05.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/059934 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor SHINO, Yusaku Michael
Aspects of the present disclosure relate to methods and systems designed to utilize antibodies and viral inactivating / lysis agents to detect SARS-CoV-2 on a microfluidic channel-based platform, for example in samples obtained from nasal swabs taken from infected individuals. The rapid and accurate point of care COVID-19 diagnostic tests that are disclosed herein can transform medical professional's testing capabilities, and in this way improve the ability to control the COVID-19 pandemic.
5.WO/2022/104465SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS DNA VACCINES
WO 27.05.2022
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CA2021/051633 Applicant UNIVERSITÉ LAVAL Inventor KOBINGER, Gary
DNA vaccine vectors composed of a vector portion and an antigen-coding portion that comprises a nucleic acid sequence encoding a severe acute respiratory syndrome coronavirus (SARS-CoV) antigen are provided. The DNA vaccines of the present disclosure are able to trigger an immune response towards SARS-CoV-2.
6.WO/2022/109430SUSTAINED RELEASE INACTIVATED VACCINES
WO 27.05.2022
Int.Class A61K 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
Appl.No PCT/US2021/060407 Applicant CASTOR, Trevor, P. Inventor CASTOR, Trevor, P.
The present invention is directed to methods and apparatus for creating a sustained release pathogen vaccine for COVID-19, influenza, HIV and other infectious human and animal viruses and pathogens using supercritical, critical, or near-critical fluids with or without polar cosolvents for simultaneously inactivating virions and pathogens, and encapsulating the inactivated virions and pathogens in biodegradable polymer nanospheres for administration to a patient. The present invention continuously inactivates SARS-CoV-2, influenza, HIV and other infectious human and animal viruses and pathogens, and nanoencapsulates the inactivated virions and pathogens in biodegradable polymer nanospheres to provide a safe and effective sustained-release vaccine, especially for the frail and elderly.
7.WO/2022/108094PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINED FORMULATION, AND COMBINED FORMULATION KIT FOR PREVENTION OR TREATMENT OF CHRONIC HEPATITIS B, EACH COMPRISING, AS ACTIVE INGREDIENT, ORAL ANTIVIRAL AGENT AND THERAPEUTIC VACCINE INCLUDING LIPOPEPTIDE AND POLY(I:C) ADJUVANT
WO 27.05.2022
Int.Class A61K 31/522
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Appl.No PCT/KR2021/013317 Applicant CHA VACCINE RESEARCH INSTITUTE CO., LTD Inventor YUM, Jung Sun
The present invention relates to a pharmaceutical composition, a pharmaceutical combined formulation, and a combined formulation kit, each comprising, as active ingredients, an oral antiviral agent and a therapeutic vaccine including a lipopeptide and a poly(I:C) adjuvant. When the pharmaceutical composition, the pharmaceutical combined agent, and the combined formulation kit are administered/used in hepatitis B patients, a remarkable synergy occurs in terms of therapeutic index for chronic hepatitis B, compared to patients who have undergone standard therapy including the administration of conventional antiviral agents, exhibiting the possibility of completely curing the disease.
8.WO/2022/109068INFLUENZA VIRUS ENCODING A TRUNCATED NS1 PROTEIN AND A SARS-COV RECEPTOR BINDING DOMAIN
WO 27.05.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/059788 Applicant VIVALDI BIOSCIENCES INC. Inventor ASPELUND, Amy
The present invention refers to a recombinant influenza virus encoding a fusion protein comprising a truncated NS1 protein and a SARS-CoV receptor binding domain, specifically a SARS-CoV-2 RBD, and its use for prophylactic treatment, a pharmaceutical preparation comprising said virus for use in prime boost vaccination and a two-component vaccine for prime boost vaccination.
9.WO/2022/109443SINGLE-CHAIN ANTIBODY AGAINST FLAVIVIRUS NS1 PROTEIN
WO 27.05.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/060468 Applicant THE REGENTS OF THE UNIVERSITY OF MICHIGAN Inventor SMITH, Janet L.
The disclosure is directed to binding agents, e.g., a single chain variable fragment (scFv) that specifically binds to a flavivirus NS1 protein, as well as compositions comprising the binding agent and a method of using such compositions to induce an immune response against a flavivirus (e.g., a dengue virus). The disclosure also provides a conjugate comprising the binding agent, and a recombinant NS1 antigen.
10.WO/2022/109484NEUTRALIZING VACCINES AGAINST HUMAN CORONAVIRUS
WO 27.05.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/060600 Applicant WISCONSIN ALUMNI RESEARCH FOUNDATION Inventor TALAAT, Adel M.
The present invention provides both QuilA-loaded chitosan (QAC)-encapsulated DNA vaccine compositions and viral vaccine compositions that encode a SARs-CoV-2 spike (S) protein, a SARs-CoV-2 nucleocapsid (N) protein, or both the S protein and the N protein. Additionally, the present invention provides methods in which the disclosed vaccines are administered to a subject to induce an immune response against SARS-CoV-2.